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Abstract: To improve the countries’ pharmaceutical situation and to monitor the progress, the World Health Organization (WHO) 
and member states developed a system of indicators to measure the respective important aspects as a prerequisite step. Level I 
indicators to assess the country’s pharmaceutical situation include the national drug policy; legislation and regulations; drug 
accessibility and affordability; essential drug list; quality control; pharmacovigilance; storage and distribution; information and 
rational use. This study is aimed to document the professional opinion of 20 pharmacy practice professionals on Libya’s current 
pharmaceutical situation, utilizing WHO indicator-based approach. The core indicators measure the most important information 
needed to understand the pharmaceutical situation in a country. A closed-end questionnaire was distributed to ten practicing 
pharmacists and ten pharmacy teaching staff members who practice pharmacy. The questionnaires were handed over personally 
and collected on the same day. The responses were analyzed using simple statistics. The results were argued in the light of the first 
author’s observation and view, being expert in this field, with reference to the other experts’ views, relevant publications’ findings 
and WHO reports’ conclusions on these indicators. Suggestions and recommendations for a proper situation assessment, planning 
and action taking are presented. Primarily, government’s commitment towards appropriate restructuring, management and 
monitoring of the pharmaceutical sector is crucial. That is to enhance the country’s pharmaceutical situation, to provide and 
sustain efficient pharmaceutical services and to improve the overall health care system’s performance.  
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1. INTRODUCTION 
The World Health Assembly resolution of 2001 on the 
World Health Organization’s (WHO) medicines strategy 
identified the four main objectives of WHO medicines (or 
drugs) strategy, namely, to frame and implement a national 
drug policy; to ensure access; to ensure quality, safety and 
efficacy; and to promote the rational use of drugs [1].  
To monitor the progress of efforts to improve the global drug 
situation, WHO has developed a system of indicators that 
measure key aspects of a country’s pharmaceutical situation 
[2]. Level I indicators is one of these tools, which measure 
the existence and performance of key national 
pharmaceutical structures and processes. These indicators 
assess progress in improving the pharmaceutical situation 
over time and enable comparison between the situation in 
countries by level of income. Level I indicators assess the 
structures and processes related to drugs’ services in the 
country. These include the national drug policy; legislation 
and regulations; drug accessibility and affordability; 
essential drug list; quality control and pharmacovigilance; 
storage and distribution; information and rational use. These 
are used to characterize the achievements and weaknesses of 
individual pharmaceutical systems and to illustrate common 
sectorial strategies and approaches. They also enable rapid 
assessment of the implementation of various components of 
the country’s pharmaceutical system. Level II and level III 
indicators describe other data of relevant assessments as 
shown in Figure 1 [2]. Level II indicators measure the 
degree of attainment or outcome of the strategic 
pharmaceutical objectives. However, level III indicators 
assess in more depth specific components of the 
pharmaceutical sector, health system, and national drug 
policy.  
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This study was to obtain a professional opinion on Libya’s 
current pharmaceutical situation, covering the WHO 
developed Level I of indicators. It was not intended to give a 
detailed analysis of the national pharmaceutical situation, but 
to provide a professional overview, to help in current 
situation analysis and in the design of appropriate 
interventions. This study sought to answer the following 
questions:  
Is there a national drug policy in Libya? Are drugs accessible 
and affordable in public and private dispensing facilities to 
treat common conditions? Are the government quality 
control procedures effective? Are the transport conditions of 
drug supply in the public sector trustable? Are drugs, 
supplying the public sector, adequately stored and handled in 
public health facility dispensaries and warehouses? Is there a 
national pharmacovigilance program, including a system for 
adverse drug reactions monitoring? Is there an independent 
drug information source for doctors and for pharmacists? Is 
there a national regulation for the pharmaceuticals’ 
marketing, promotion or advertising; for national drug 
formularies; for hospitals’ drug and therapeutics committees; 
for the standard treatment guidelines; for hospitals’ 
antimicrobial resistance committees; for the lists of 
prescription-only and over-the counter drugs; or for the 
generics’ prescribing? Is there a national obligatory 
continuing education program on pharmaceuticals for 
doctors or for pharmacists? Are drugs rationally prescribed 
(by doctors), dispensed (by pharmacists) and used (by 
patients)? 
2. MATERIALS AND METHODS 
A closed-end questionnaire was designed as per the WHO 
selected indicators for the measurement of a country’s 
pharmaceutical situation. It included questions addressed to 
practicing pharmacists; half of them were Pharmacy Practice 
university teaching staff members as well.  
The presented questions are shown at the Results section. 
Study’s ethical approval was obtained from the Ministry of 
Health. The questionnaire was first piloted to 20% of the 
targeted participants. Then it was distributed to two groups 
of practicing pharmacists, ten in each group. The major job 
of the first group’s participants was to practice pharmacy 
within a community pharmacy setting. The second group’s 
participants were university teaching staff members, holding 
at least a PhD in Pharmacy Practice and teaching Pharmacy 
Practice, while they continue to practice pharmacy within a 
community pharmacy. The questionnaires were handed over 
personally, without interference with the participants, and 
were completed and collected on the same day. Response 
rate was 100%. The results were analyzed using simple 
statistics. 
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3. RESULTS 
Seven (70%) of the first group participants and five (50%) of 
the second group participants were females. 
Collected responses to the given questions were as 
following: 
 
Question 
Yes 
 
No.(%ag
e) 
No 
 
No.(%ag
e) 
I’m not 
sure 
No.(%ag
e) 
Do you think that there is a national drug policy in Libya? 3(15%) 13(65%) 4(20%) 
Do you think that all key pharmaceutical products are accessible in the public sector by 
all people? 
1(5%) 18(90%) 1(5%) 
Do you think that all key pharmaceutical products are affordable in the private market to 
all people?  
2(10%) 12(60%) 6(30%) 
Do you trust the government quality control procedures? 2(10%) 16(80%) 2(10%) 
Do you trust the transport conditions of drug supply in the public sector? 4(20%) 6(30%) 10(50%) 
Do you trust the storage conditions of drug supply in the public sector? 2(10%) 6(30%) 12(60%) 
Do you think that there is a national pharmacovigilance program, including a system for 
adverse drug reactions monitoring? 
0(0%) 16(80%) 4(20%) 
Do you think that there is an independent drug information source for doctors? 8(40%) 8(40%) 4(20%) 
Do you think that there is an independent drug information source for pharmacists? 9(45%) 9(45%) 2(10%) 
Do you think that there is a national regulation for the pharmaceuticals marketing, 
promotion or advertising?  
2(10%) 12(60%) 6(30%) 
Do you think that there is a national regulation for national drug formularies? 3(15%) 15(75%) 2(10%) 
Do you think that there is a national regulation for hospitals’ drug & therapeutics 
committees? 
7(35%) 8(40%) 5(25%) 
Do you think that there is a national regulation for the standard treatment guidelines? 3(15%) 3(15%) 14(70%) 
Do you think that there is a national regulation for hospitals’ antimicrobial resistance 
committees? 
4(20%) 11(55%) 5(25%) 
Do you think that there is a national regulation for the lists of prescription-only & over-
the counter drugs? 
4(20%) 12(60%) 4(20%) 
Do you think that there is a national regulation for the generics’ prescribing? 3(13%) 13(65%) 4(20%) 
Do you think that there is a national obligatory continuing education program on 
pharmaceuticals for doctors? 
4(20%) 14(70%) 2(10%) 
Do you think that there is a national obligatory continuing education program on 
pharmaceuticals for pharmacists? 
9(45%) 11(55%) 0(0%) 
Do you think that drug irrational prescribing (by doctors) exists? 13(65%) 2(10%) 5(25%) 
Do you think that drug irrational dispensing (by pharmacists) exists? 14(70%) 3(15%) 3(15%) 
Do you think that drug irrational use (by patients) exists? 12(60%) 4(20%) 4(20%) 
 
4. DISCUSSION 
Opinions of the majority of the study participants on Libya’s 
pharmaceutical situation’s presented indicators were 
negative, or at least they were unaware of the situation. 
These responses are in line with the authors’ observation, 
with national experts’ views, other related studies’ findings 
and WHO’s reports [3-13].   
In Libya, it is well observed that there is a weak priority 
setting, lack of planning and bureaucratic budgetary 
processes. Moreover, there is a systemic weakness, with a 
lack of an adequate drug legislation and regulations; an 
institutional instability and a lack of reliable data. That led to 
improperly functioning drug regulatory authority with 
adequate resources and infrastructure to enforce the poorly 
developed legislation and regulations [4-5, 9-13]. National 
drug policy was developed incomplete in 2003, never 
circulated, never implemented, never monitored and never 
updated. However, most world countries report the presence 
of extensive legal and regulatory framework, covering all 
aspects of the pharmaceutical sector. In 2011, 81% of the 
world countries had a national drug policy and 62.6% 
countries had an implementation plan integrated within the 
health strategy [14]. 
Currently, there is no documented/written national policy, 
regulation or system for the selection of items or 
specifications of the national specifications list or essential 
drug list at the Libyan Ministry of Health. No pharmaco-
economic analysis for the selection of new items was ever 
conducted. Furthermore, the existing list does not include 
several essential items that are recommended by the WHO 
[3-5, 8-11], while nearly all countries have a system of 
national specifications or essential drug list [15].  
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Continuous organizational drug supply difficulties and acute 
shortages exist, with an unguaranteed transportation, storage 
or distribution system [3-5, 10, 13]. Moreover, cold chain is 
not necessarily well maintained, especially in remote areas. 
Partial availability and inadequate public accessibility to 
essential drugs is reported at the public health facilities, with 
time and regional variations [4-5, 10]. Private market 
observes frequent drug shortages and large prices increases, 
with a lack of government control or monitoring, evidencing 
questions about drug affordability as well. The drug quality 
control administration is relatively weak and unstable, with 
no government serious official commitment or support. 
Quality control lacks necessary legislation, regulations, 
policy, system and special operation procedures, with 
insufficient equipment and a lack of enough trained 
personnel. No pharmacovigilance programs are taking place. 
Accordingly, counterfeit and substandard products are 
currently expected to circulate in the country freely, with 
estimates of rates equal to or higher than those in countries 
of high prevalence [5-7]. Nevertheless, on a personal 
communication, the Director of Drugs’ Quality Control, the 
National Centre for Food and Drug Control, Tripoli, 
indicated that none of the referred samples to the centre of 
those illegally imported drug products has shown to be 
counterfeit.  
Registration or licensing of pharmaceutical manufacturers 
and importers is implemented, with some weaknesses [5, 12-
13]. Some private pharmacies and wholesalers operate with 
no licenses. Owners and dispensers at some of them are not 
pharmacists. Transportation, storage and distribution system 
is not guaranteed. Registration or marketing authorization of 
pharmaceutical products is not taking place in Libya.  
No national standard treatment guidelines exist. Hospitals’ 
drug and therapeutics committees are formulated in some 
hospitals with no country regulation or central guidelines. 
Moreover, there is no national policy to enforce or promote 
generics’ prescribing or dispensing, while regulations around 
the world are in this direction. There is no country system for 
the lists of prescription and non-prescription drugs, whilst 
most of countries have three lists, including a list of the 
pharmacy or pharmacist drugs, which are regularly updated. 
Irrational drug use exists in doctors’ prescribing, in 
pharmacists’ dispensing and in patients’ use. Drug 
promotion activities are not regulated in Libya, with frequent 
illegal, unethical and unprofessional practices [6]. 
A government’s commitment towards appropriate 
restructuring, management and monitoring of the 
pharmaceutical sector is crucial, in order to enhance the 
country’s pharmaceutical situation, to provide and sustain 
efficient pharmaceutical services, and to improve the overall 
national health care system’s performance. Focus on the 
continuous professional development is a prerequisite. The 
developed national drug policy needs to be reviewed, 
updated and circulated. A standardized evidence-based 
process of drugs’ selection that complies with the WHO 
recommendations is required. A properly structured stable 
and professional drug procurement and supply system, with 
appropriate funding, needs to be established. The entire 
process of registration, quality control, pharmacovigilance 
and information requires further consideration and 
improvement. Additionally, strategies for the adherence to 
standard treatment guidelines and drug therapeutic 
committees; the promotion of good prescribing and 
dispensing practices, and the promotion of drug rational use 
need to be properly established. Private sector needs to be 
empowered and monitored, in order to represent a partner to 
the public sector, rather than a competitor. 
In fact, the proper assessment of the country’s 
pharmaceutical situation should be a governmental 
commitment and an institutional responsibility. That is 
recommended to be conducted using a standardized 
methodology. The outcome of the assessment is to be used to 
target different programs and resources related to the 
pharmaceutical legislation, policy, supply, quality control 
and rational use.  
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